Hadassah

Hadassah, Palestinian, and German Triumvirate Rescues Children with Severe Immune Defects

Tuesday, May 17 2016

A tripartite collaboration initiated by the Hadassah Medical Center with Palestinian and German colleagues, dedicated to the discovery and characterization of congenital diseases of the immune system, has led to the discovery of a new genetic mutation, a new disease, and the first successful bone marrow transplant in the world to cure a child with this condition. This scientific journey was highlighted in the hematology journal, Blood and was chosen as one of the top ten research articles of the year by this prestigious publication.

In March of this year, Hadassah hosted the inaugural international conference of this collaboration, reports Dr. Polina Stepensky, head of the Pediatric Bone Marrow Transplantation Center in the Department of Pediatric Hemato-Oncology, who initiated the collaboration together with Prof. Dr. Klaus Warnatz of the University of Freiburg’s Center for Chronic Immunodeficiency in 2012. Over one hundred doctors, nurses, transplant coordinators, and technicians from hospitals all over Israel, the Palestinian Authority (Ramallah, Hebron, Bethlehem, Jericho, Jenin) and representatives from both the Israeli and Palestinian Ministries of Health attended the conference to share their latest experiences in clinical and basic research on pediatric immunological diseases.

Through this collaboration, “over 70 children have been diagnosed with specific immunodeficiency diseases and about 40 have received successful bone marrow transplants at Hadassah,” Dr. Stepensky says. The tripartite project is now managed by Dr. Stepensky, Prof. Warnatz, and Dr. Omar Abu Zaitoun of Nablus. “I have a long-standing collaboration with Palestinian physicians-- especially Dr. Omar Abuzaitoun,” relates Dr. Stepensky. At first, the children with immunological diseases are identified by dedicated Palestinian physicians.  Upon referral to Hadassah, Dr. Stepensky examines them and refers them to Prof. Orly Elpeleg, head of Hadassah’s Department of Genetic and Metabolic Diseases, for a comprehensive genetic analysis called whole exome sequencing. This sequencing is a novel revolutionary technology which searches through a person’s genes and finds variations in the “coding region” called exons. “Once we have the genetic results,” Dr. Stepensky explains, “we perform immunological studies, both here and more advanced studies in Germany. After the specific immunological genetic defect is identified, many of the young patients come to Hadassah for transplantation to cure them.” 

Over 10 articles highlighting the work of this collaborative project have been published in leading scholarly journals in the field of immunology.

In 2015, Dr. Stepensky and Prof. Warnatz received a trilateral grant from the German Research Foundation (DFG), the central, self-governing research funding organization in Germany, which funds and supports groundbreaking scientific research. The grant enabled them to mount the conference.

Eager to continue with this research journey, Dr. Stepensky notes: “This collaboration is an amazing example of opening new horizons in science and medicine, finding new friends and, together, identifying new genes and new genetic mutations, along with the mechanisms through which these genes malfunction—with the end result of curing many children.”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More